19 May 2013
Keywords: clinical, trial, news, brief, canadian, firm, aeterna
Article | 17 February 1998
Canadian firm Aeterna has started enrolling patients in a Phase I/IItrial of Psovascar, an angiogenesis inhibitor based on its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 February 1998
19 February 1998
17 May 2013
© 2013 thepharmaletter.com